Sign in
Not yet taking people in United StatesPhase 1/2

Sirolimus given into the brain to prevent hydrocephalus after brain bleeding

Tests sirolimus in adults with hydrocephalus after bleeding in the brain.

Key facts

Who runs it
Massachusetts General Hospital
Where
Boston, United StatesSee the site
Trial code
Registry title
Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage
Status
Not yet recruiting
Phase
Phase 1/2
People taking part
15 people, planned
Starts
1 Jan 2027
Expected to end
31 Dec 2027
Type of study
Interventional
Treatments tested
  • Sirolimus (Rapamune®)
Record updated
25 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with severe bleeding in the brain from a burst aneurysm, with blood in the brain's fluid spaces. They must need a temporary brain drain (EVD) as part of usual care.

Age
18 years and older
Sex
All sexes
Disease stage
Aneurysmal subarachnoid hemorrhage (bleeding around the brain from a burst aneurysm), Hunt Hess grade IV to V (severe). Scans must show bleeding into the brain's fluid spaces (intraventricular hemorrhage).
Earlier treatment
An external ventricular drain (EVD) must be placed as part of standard care. People should join soon after, ideally within 24 hours of EVD placement.

Main reasons for not taking part

  • Already depending on a ventriculoperitoneal shunt (a permanent brain fluid drain)
  • Severely weakened immune system
  • Uncontrolled body-wide infection not related to the bleeding
  • Pregnancy
  • Life-support expected to be stopped within 24 hours

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age ≥18 years
  • Diagnosis of aneurysmal subarachnoid hemorrhage (aSAH)
  • Hunt Hess grade IV to V
  • Radiographic evidence of intraventricular hemorrhage (IVH)
  • Clinically indicated EVD placement as part of standard neurocritical care
  • Ability to enroll during the acute post-hemorrhagic inflammatory period, ideally within 24 hours of EVD placement

Who cannot take part

  • Anticipated withdrawal of life-sustaining therapy within 24 hours
  • Inability to safely receive investigational ventricular therapy
  • Uncontrolled systemic infection unrelated to hemorrhage
  • Pre-existing ventriculoperitoneal shunt dependence
  • Severe baseline immunosuppression
  • Pregnancy

Where in United States

  • Massachusetts General Hospital Lunder 4 OR for adult surgeriesBoston, United StatesContact: Carla Fortes, BANot yet recruiting

About the trial

What the trial wants to find out

Hydrocephalus is a serious condition in which fluid builds up inside the brain, often requiring lifelong surgical placement of a shunt to drain excess cerebrospinal fluid (CSF). One of the most common causes of hydrocephalus is bleeding into the brain's fluid spaces after aneurysm rupture, prematurity, or infection. Currently, no medication exists to prevent hydrocephalus from developing after these injuries. The investigators' recent research suggests that hydrocephalus may result not only from blocked fluid pathways but also from harmful inflammation within the brain's ventricular system. The investigators discovered that inflammation activates the choroid plexus, the tissue that produces CSF, causing excessive CSF production and inflammatory injury to the ventricular lining and surrounding brain tissue. The investigators also identified inflammatory biomarkers and extracellular vesicles in human CSF that may enable real-time monitoring of these disease processes.

Read full original descriptionShow less

In this project, the investigators will perform a first-in-human pilot study testing whether targeted "intraventricular mTOR inhibition" can reduce ventricular inflammation and prevent hydrocephalus after severe brain hemorrhage. The medication will be delivered via temporary ventricular drains already in place as part of routine clinical care. The investigators will study safety, inflammation, CSF production, brain imaging changes, and whether patients ultimately require permanent shunts. Although this initial study focuses on adults with hemorrhage-related hydrocephalus, our long-term goal is to develop non-surgical therapies that could help children with hydrocephalus caused by prematurity or infection, especially in regions where access to neurosurgical care and shunt surgery is limited.

The group in the trial

  • Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain HemorrhageTreatment being tested

    The investigators will conduct a prospective, single-center, phase Ib/IIa, biomarker-rich translational pilot study evaluating intraventricular mTOR inhibition in adults with severe aneurysmal subarachnoid hemorrhage (aSAH) who require external ventricular drain (EVD) placement as part of routine neurocritical care management. The central objective of the study is to determine whether early modulation of ventricular immune-secretory signaling is feasible, biologically active, and capable of altering inflammatory CSF physiology and ventricular remodeling following hemorrhage.

    Treatment: Sirolimus (Rapamune®)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
VENTURE-PHH: Ventricular mTOR Inhibition to Prevent Hydrocephalus After Brain Hemorrhage
Plain-language title
Sirolimus given into the brain to prevent hydrocephalus after brain bleedingGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
25 June 2026